[Antiangiogenic therapy]

Arch Soc Esp Oftalmol. 2005 Aug;80(8):435-6. doi: 10.4321/s0365-66912005000800001.
[Article in Spanish]
No abstract available

Publication types

  • Editorial

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use*
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Aptamers, Nucleotide / therapeutic use
  • Choroidal Neovascularization / drug therapy*
  • Choroidal Neovascularization / etiology
  • Clinical Trials as Topic
  • Eye Proteins / metabolism
  • Humans
  • Macular Degeneration / complications
  • Macular Degeneration / drug therapy
  • Nerve Growth Factors / metabolism
  • Photochemotherapy
  • Ranibizumab
  • Serpins / metabolism
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Aptamers, Nucleotide
  • Eye Proteins
  • Nerve Growth Factors
  • Serpins
  • Vascular Endothelial Growth Factor A
  • pigment epithelium-derived factor
  • pegaptanib
  • Ranibizumab